The Cancer Genomics and Tumor Immunotherapy Symposium: A Clinical Perspective is a key educational event, jointly hosted by the Cancer Genomics Program (CGP) and the Tumor Immunotherapy Program (TIP) at the Princess Margaret Cancer Centre. The objective of this Symposium is to provide a clinical and translational perspective on cancer genomics and tumor immunotherapy by highlighting emerging therapies and technologies as they apply to precision cancer medicine at the point of care. Participants will learn about novel genomic approaches for diagnosis, the clinical development of tumor-derived DNA as a biomarker for cancer, immunogenomic-based drug development, response and resistance mechanisms to immune checkpoint therapy, and precision oncology for young people.

This one-day symposium will be held at the MaRS Discovery District in downtown Toronto:

MaRS Discovery District 
101 College Street, 
Toronto, ON  
M5G 1L7


Confirmed speakers include:

Philippe Bedard, MD, Princess Margaret Cancer Centre

Trevor Pugh, PhD, Princess Margaret Cancer Centre

Max Diehn, MD, PhD, Stanford University

Frederick Locke, MD, Moffitt Cancer Center

Meredith Irwin, MD, Hospital for Sick Children

Morag Park, PhD, McGill University

Adrian Sacher, MD, Herbert Irving Comprehensive Cancer Center

Pamela L. Schwartzberg, MD, PhD, National Human Genome Research Institute

Juan Carlos Zúñiga-Pflücker, PhD, Sunnybrook Research Institute


Target Audience for the 2017 Cancer Genomics and Tumor Immunotherapy Symposium:

  • Oncologists: Medical, Radiation, Surgical
  • Pathologists
  • Clinical Geneticists
  • Genetic Counselors
  • Laboratory Directors
  • Laboratory Technicians
  • Oncology Nurses
  • Bioinformaticians
  • Basic and Translational Scientists
  • Basic, Translational and Clinical Trainees
  • Pharmaceutical Representatives


Topics to be discussed in a presentation or panel include:

  • Clinical Applications of High Throughput Sequencing-Based Circulating Tumor DNA Analysis
  • Precision Oncology for Young People
  • Update on the Cancer Genomics Program at Princess Margaret
  • Anti-CD19 CAR-T Cell Therapy for Aggressive B Cell Lymphoma
  • The Impact of Tumor Microenvironment on Immune Response in Triple Negative Breast Cancer
  • Immunogenomics as a Tool to Guide Rational Drug Development and Clinical Care
  • Mechanisms of T Cell Exhaustion
  • Unexpected T Cells Recognizing Tumour Associated Antigens